Disclaimer.
ScyFIX MCN 700 and 600 therapy devices both have CE Marks. They are non-invasive, safe and approved for sale in the European Union and other countries honouring the CE Mark. Please note that ScyFIX has discontinued distributing the ScyFIX 600 product in anticipation of the new ScyFIX 700 Eye Therapy System which was introduced just recently an will be shipped to customers in the coming months. Distribution of the ScyFIX 600 products has been taken over by Prospectus AB based in Stockholm, Sweden (EU). For any ScyFIX 600 sales or customer service questions, please contact Prospectus, owner of the domain www.scyfix.org and proud proprietor and distributor for all ScyFIX 600 products and accessories. Prospectus can be contacted via email to prospectus@prospectus.se 
By using the device, appliances and nutritional supplements and accepting the conditions in this disclaimer, you acknowledge and agree that neither Prospectus, ScyFIX nor its heirs or assigns, shall be liable for any direct or indirect consequential damages to you or any other persons or property that may be exposed to the device, appliances and nutritional supplements. If so required by law in your country, you shall only use this device under the supervision of a medical professional licensed to dispense it and monitor your treatment. It is entirely the buyer's (be it a patient, a doctor or a distributor) own responsibility to establish whether the products are legal to import and use in the buyer's country. The ScyFIX MCN 600 is not available for commercial sale in the USA. An application for US approval for the ScyFIX MCN 700 Eye Therapy System will be filed later this year.

 
     

Breaking News! The ScyFIX 700 MCN Therapy is the only patented Micro Current Neuromodulation (MCN) device approved in Europe for the treatment of Retinitis Pigmentosa. Compelling Clinical Results: Retinitis Pigmentosa (RP) is a degenerative disease, and improvement in visual fields, visual acuity, or contrast sensitivity is not expected. In the RP trial, best corrected visual acuity either improved or remained stable in 94% of patients and improved in 22% of the population. Visual field improved in 63% of the patients. Patients are now using mobile phones, reading newspapers, seeing faces of family members and threading needles, none of these day to day activities were possible for these patients before using the ScyFIX MCN device. Similar compelling results have been achieved in our Dry Age-Related Macular Degeneration (“ARMD”) trial as well.